Genmab Collaborates With Lilly On DuoBody Platform
Genmab enters collaboration with Eli Lilly to use and evaluate Genmab's DuoBody technology for bispecific antibodies.
Genmab A/S has entered into a research collaboration with Eli Lilly to use and evaluate Genmab's DuoBody technology platform for the creation of bispecific antibodies. Under the collaboration, Lilly will initially evaluate the DuoBody technology platform in
house. The financial terms of the agreement have not been disclosed. This agreement will not have a material impact on Genmab's financial results and cash position.
Source: Genmab A/S
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
